Truist lowered the firm’s price target on Exelixis (EXEL) to $49 from $56 and keeps a Buy rating on the shares. Cabo missed expectations in Q2, and while there was commercial volume growth, other factors were a headwind, and the reported $520M in sales missed the Street, the analyst tells investors in a research note. The firm is incrementally more positive following management’s comments on STELLAR-303.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target lowered to $45 from $50 at RBC Capital
- Exelixis’s Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
- Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns
- Exelixis’s Long-Term Growth Potential: Buy Rating Backed by Strong Fundamentals and Promising Drug Pipeline
- Exelixis Reports Q2 2025 Financial Results and Updates